Gemcitabine + E7389 + Cisplatin
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Apr 16, 2010 → Jul 20, 2016
NCT ID
NCT01126749About Gemcitabine + E7389 + Cisplatin
Gemcitabine + E7389 + Cisplatin is a phase 1/2 stage product being developed by Eisai for Bladder Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01126749. Target conditions include Bladder Cancer.
What happened to similar drugs?
10 of 20 similar drugs in Bladder Cancer were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01126749 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Bladder Cancer